Robin is the US head of our risk advisory practice. Robin's risk advisory expertise involves working with global clients to identify, mitigate and manage key risks across their businesses in a holistic and strategic manner, across business units and geographies, which includes analysing the current and emerging risks within the context of our client's commercial goals and their risk culture and appetite.
Robin's pragmatic approach to the practice of law is informed by her experience, having served as in-house antitrust and litigation counsel at Swiss healthcare company Novartis and UK alcohol beverage leader Diageo before becoming North American General Counsel of Sandoz, the generics division of Novartis.
Whether involving pharmaceuticals, consumer products or other industries, Robin has advised her clients on a wide variety of issues and directed material litigation and government investigations to positive results. As a former general counsel of a multibillion-dollar company, Robin knows first-hand the importance of providing prompt, accurate and practical advice on legal and compliance issues, particularly in the context of balancing complex business objectives. Robin also understands the challenges with managing outside counsel, having redesigned and run the Novartis Preferred Firm Program globally.
Robin litigates complex, commercial disputes, class actions and multi-jurisdictional cases before US federal and state courts, and represents clients in government enforcement actions by the Federal Trade Commission and Department of Justice, as well as the HHS Office of the Inspector General. She has defended clients in qui tam matters in many locales and in investigations and litigation by numerous State Attorneys General. Robin also advises companies with respect to the antitrust issues arising in mergers and acquisitions, joint ventures, trade association activities, distribution practices, pricing programmes and other aspects of competitor and customer communications and associations.